Skip to main content
SAMJIN PHARMACEUTICAL CO.,LTD logo

SAMJIN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 005500 ISIN · KR7005500004 KO Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2024-03-07 AGM Information
Country KR South Korea
Listing KO 005500

About SAMJIN PHARMACEUTICAL CO.,LTD

https://www.samjinpharm.co.kr/

Samjin Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes a wide range of over-the-counter (OTC) and prescription drugs, offered in various formulations such as oral, drop, and injectable forms. Notable products include the analgesic Gevorin, the antiplatelet agent Plavix, and the hypercholesterolemia treatment Newstatin-R. A central part of its strategy is a strong commitment to R&D, focusing on creating innovative new drugs to address diseases with high unmet medical needs. The company actively develops novel therapeutics for severe conditions, including cardiovascular, respiratory, and gastrointestinal diseases, with the goal of becoming a global pharmaceutical innovator.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company (Samjin Pharmaceutical) is holding its AGM on a date that coincides with other companies' meetings. Since this is a regulatory disclosure regarding the scheduling of a shareholder meeting rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2024-03-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and Korea Exchange. It details the share ownership, changes in shareholding, and contractual arrangements (such as stock collateral agreements) of major shareholders and their special relations. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and related party interests.
2024-02-23 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Samjin Pharmaceutical. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and meeting notice provided to shareholders, which falls under the Proxy Solicitation & Information Statement category.
2024-02-19 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement from Samjin Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the expected payment date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2024-02-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as an 'Insider Trading Report' or 'Director's Dealing' report) where company executives or major shareholders disclose their holdings or changes in holdings of the company's stock. This aligns perfectly with the 'Director's Dealing' (DIRS) category.
2024-01-05 Korean
매매거래정지및정지해제(중요내용공시)
Delisting Announcement Classification · 1% confidence The document is a short, formal regulatory notice regarding the suspension and resumption of trading for Samjin Pharmaceutical's stock due to a material disclosure (business suspension). It follows the standard format of a regulatory announcement issued to a stock exchange, which does not fit into specific categories like financial reports or shareholder communications. Therefore, it is classified as a general regulatory filing.
2023-12-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.